Association between opium abuse and comorbidity in diabetic men

American Journal on Addictions

Volumn 15, Issue 6, 2006, Pages 468-472

  Shiri, Rahman ^a,c   Hassani, Kobra Falah ^a   Ansari, Mostafa ^b  

^a UNIVERSITY OF TAMPERE   (Finland)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NONE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; ERECTILE DYSFUNCTION; HUMAN; IRAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; OPIATE ADDICTION; PREVALENCE; RISK ASSESSMENT; SAMPLE SIZE; SELF REPORT; SMOKING; SOCIOECONOMICS; STATISTICAL ANALYSIS; TEA;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; DEPRESSIVE DISORDER; DIABETES MELLITUS; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OPIUM; RURAL POPULATION; SMOKING; STATISTICS; TEA; URBAN POPULATION;

EID: 33845909303     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490601000421     Document Type: Article

References (30)

1. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann N Y Acad Sci. 2004;1025:446-457.
2. Monteiro MG. A World Health Organization perspective on alcohol and illicit drug use and health. Eur Addict Res. 2001;7:98-103.
3. Millson PE, Challacombe L, Villeneuve PJ, et al. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health. 2004;95:99-103.
4. Prochaska JJ, Sorensen JL, Hall SM, et al. Predictors of health functioning in two high-risk groups of smokers. Drug Alcohol Depend. 2005;78:169-175.
5. Ahmadi J, Sharifi M, Mohagheghzadeh S, et al. Pattern of cocaine and heroin abuse in a sample of Iranian population. German Journal of Psychiatry. 2005;8:1-4.
6. Schmitz N, Kruse J, Kugler J. Disabilities, quality of life, and mental disorders associated with smoking and nicotine dependence. Am J Psychiatry. 2003;160:1670-1676.
7. Burns JM, Martyres RF, Clode D, Boldero JM. Overdose in young people using heroin: associations with mental health, prescription drug use and personal circumstances. Med J Aust. 2004;181:S25-S28.
8. La Pera G, Franco Giannotti C, Taggi F, Macchia T. Prevalence of sexual disorders in those young males who later become drug abusers. J Sex Marital Ther. 2003;29:149-156.
9. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage. 2003;26:1055-1061.
10. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84:50-56.
11. Noorbala AA, Bagheri Yazdi SA, Yasamy MT, Mohammad K. Mental health survey of the adult population in Iran. Br J Psychiatry. 2004;184:70-73.
12. MacDonagh R, Ewings P, Porter T. The effect of erectile dysfunction on quality of life: psychometric testing of a new quality of life measure for patients with erectile dysfunction. J Urol. 2002;167:212-217.
13. Althof SE. Quality of life and erectile dysfunction. Urology. 2002;59:803-810.
14. Ansong KS, Lewis C, Jenkins P, Bell J. Help-seeking decisions among men with impotence. Urology. 1998;52:834-837.
15. Ahmadi J, Maharloov N, Alishahi M. Substance abuse: prevalence in a sample of nursing students. J Clin Nurs. 2004;13:60-64.
16. Ahmadi J, Toobaee S, Kharras M, Radmehr M. Psychiatric disorders in opioid dependants. Int J Soc Psychiatry. 2003;49:185-191.
17. Beck AT, Brown G, Steer RA. Beck Depression Inventory II Manual. San Antonio, Tex.: The Psychological Corporation; 1996.
18. Lasa L, Avuso-Mateos JL, Vazquez-Barquero JL, Diez-Manrique FJ, Dowrick CF. The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis. J Affect Disord. 2000;57:261-265.
19. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, five-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326.
20. Giuliano F, Chevret-Measson M, Tsatsaris A, Reitz C, Murino M, Thonneau P. Prevalence of erectile dysfunction in France: results of an epidemiological survey of a representative sample of 1004 men. Eur Urol. 2002;42:382-389.
21. Pourshams A, Saadatian-Elahi M, Nouraie M, et al. Golestan cohort study of esophageal cancer: feasibility and first results. Br J Cancer. 2005;92:176-181.
22. Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005;14:106-123.
23. Sathe RS, Komisaruk BR, Ladas AK, Godbole SV. Naltrexone-induced augmentation of sexual response in men. Arch Med Res. 2001;32:221-226.
24. Brennemann W, Stitz B, Van Ahlen H, Brensing KA, Klingmuller D. Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone - a double-blind study. J Androl. 1993;14:407-410.
25. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377-384.
26. Araujo AB, Johannes CB, Feldman HA, Derby CA, McKinlay JB. Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2000;152:533-541.
27. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. Life satisfaction in male erectile dysfunction. Int J Impot Res. 1997;9:141-148.
28. Levine LA, Kloner A. Importance of asking questions about erectile dysfunction. Am J Cardiol. 2000;86:1210-1213.
29. Abnet CC, Saadatian-Elahi M, Pourshams A, et al. Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev. 2004;13:1068-1070.
30. Safarinejad MR. Prevalence and risk factors for erectile dysfunction in a population-based study in Iran. Int J Impot Res. 2003;15:246-252.